# Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects

> **NCT02855073** · PHASE2 · UNKNOWN · sponsor: **Shanghai AbelZeta Ltd.** · enrollment: 28 (estimated)

## Conditions studied

- Defect of Articular Cartilage
- Knee Osteoarthritis

## Interventions

- **BIOLOGICAL:** ReJoinTM
- **DRUG:** Sodium Hyaluronate

## Key facts

- **NCT ID:** NCT02855073
- **Lead sponsor:** Shanghai AbelZeta Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2018-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02855073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02855073, "Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02855073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*